Galectin Therapeutics Inc.
GALTDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 13, 2026
9dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
GALT Earnings Report
EPS Est: $-0.09 | FQ end 2026-06
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
belapectin | Phase 3 | Prevention of Esophageal Varices | - | - |
GR-MD-02 | Phase 2 | Psoriasis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Galectin Therapeutics Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Galectin Therapeutics Inc.'s (GALT) pipeline across Phase 3, Phase 2. Its lead program is belapectin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Galectin Therapeutics Inc.'s next FDA catalyst?→
Galectin Therapeutics Inc.'s (GALT) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GALT biotech catalysts?→
Add GALT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Galectin Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.